期刊
ACS NANO
卷 15, 期 6, 页码 9627-9637出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.0c10180
关键词
SARS-CoV-2; COVID-19; mRNA vaccine; lipid nanoparticles; ionizable lipids
类别
资金
- Lewis Trust
This study presents the design of an mRNA vaccine based on lipid nanoparticles (LNPs) encapsulated SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc), demonstrating its potential to induce strong immune responses and produce neutralizing antibodies, making it a promising candidate for a COVID-19 vaccine.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple, and rapid platform for immunization, and therefore have been employed in recent studies toward the development of a SARS-CoV-2 vaccine. Herein, we present the design of an mRNA vaccine, based on lipid nanoparticles (LNPs)-encapsulated SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc). Several ionizable lipids have been evaluated in vivo in a luciferase (luc) mRNA reporter assay, and two leading LNPs formulations have been chosen for the subsequent RBD-hFc mRNA vaccine strategy. Intramuscular administration of LNP RBD-hFc mRNA elicited robust humoral response, a high level of neutralizing antibodies and a Th1-biased cellular response in BALB/c mice. The data in the current study demonstrate the potential of these lipids as promising candidates for LNP-based mRNA vaccines in general and for a COVID19 vaccine in particular.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据